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(decreased) could provide such justification. Otherwise, I would suggest removing this suggestion from the abstract since it is not based on the obtained results.
REVIEWER
Huan Song University of Iceland, Iceland REVIEW RETURNED 28-Jul-2018
GENERAL COMMENTS
This paper described the prevalence, and its related risk factors, of serologically defined atrophic gastritis among two populations. Basically, the laboratory and statistical methods applied in this paper are proper. However, I think the research question is not novel, and since no biopsy diagnosis was used for confirming purpose, the results of this study have limited clinical significance. Specifically, here are my comments:
1. My major concern is the accuracy of serologically defined atrophic gastritis among the studied population. The ELISA method was used for PGI and PGII tests and the authors stated the cut-off point used in their study. However, no information was provided for demonstrating the accuracy of this test. a) the cut-off point provided by the manufacturer is based on European population (right?), the question that how does it fit the Israel population needs to be answered first (authors listed some studies in the discussion part, but no validation study was performed in Israel population)----my suggestion is either adding a pilot study to demonstrate the used cut-off point is rational for Israel population, or perform sensitivity analyses for showing the robust of the results to the selection of cut-off point; b) the ELISA method is very sensitive, so I suggest authors provided more information about the lab procedure: e.g. any quality control? all samples were tested in one day? in the same lab?
2. 'Study design and population' part : please specify how the weight and height were measured? or they are self-reported?
3. In the discussion part, the authors summarized evidence of risk factors from previous studies worldwide. I might suggest the authors mention studies from the same region (Israel or neighbor Reply: We agree with Prof. Leja. Accordingly, we edited the section on study limitations, and added the following text "Our study has some limitations. First, locally validated serum pepsinogen assays are lacking, for comparison with histological examination of gastric biopsies". We also mentioned that the validity of the assay might differ between the Arab and Jewish populations. We clarified this point in the text. Please see page 21, last paragraph.
Other major comments:

1) Since cut-off values are test-type specific, this is not acceptable to discuss 'commonly used cut-off values' for pepsinogen detection apart from mentioning the type of the test (RIA, ELISA, latexagglutination). In absolute values pepsinogen levels would differ depending on whether ELISA or latexagglutination test is being used. The cut-off values authors have applied are generally accurate in a Caucasian population, and therefore the use of this cut-off in the current study population is justified. However, when discussing any of the published evidence, this should not be done without mentioning the test-type.
Reply: In agreement with the reviewer, we edited the relevant paragraph. Since we used Biohit ELISA kits for the measurement of serum pepsinogens, we limited the discussion to this method and cited the relevant evidence. Please see page 18 paragraph 2.
2) The test-type for pepsinogen detection has to be included to the abstract (at least by mentioning that this has been an ELISA test).
Reply: Following the reviewer's suggestion, we added the test type to the abstract. Please see the revised abstract, page 3, paragraph 2.
3) This should be indicated whether data on previous H. pylori eradication therapy have been collected within the interviews. If yes, this should be a part of the analysis. If no, this should be discussed in the limitations of the study.
Reply: In the current study, we used anonymized archived sera and data that were collected in a previous cross-sectional study on cardiovascular risk factors about a decade ago. Data were not collected in the original study on previous H. pylori eradication therapy. In view of the reviewer's comment, we added this point to the study limitations. Please see page 21, last line and page 22 paragraph 1.
4)
The Reply: We thank Prof. Song for the valuable and positive comments. We note that the few studies that addressed the correlates of atrophic gastritis in general population samples were usually limited to a single ethnic group and investigated a limited number of independent variables. Our study is novel in that it compared the prevalence correlates of atrophic gastritis between two ethnically diverse population groups that display different trends patterns of gastric cancer incidence rates.
Specifically, here are my comments:
My major concern is the accuracy of serologically defined atrophic gastritis among the studied population. The ELISA method was used for PGI and PGII tests and the authors stated the cut-off point used in their study. However, no information was provided for demonstrating the accuracy of this test. a) the cut-off point provided by the manufacturer is based on European population (right?), the question that how does it fit the Israel population needs to be answered first (authors listed some studies in the discussion part, but no validation study was performed in Israel population)----my suggestion is either adding a pilot study to demonstrate the used cut-off point is rational for Israel population, or perform sensitivity analyses for showing the robust of the results to the selection of cut-off point;
Reply: Indeed, the cutoff values used were not validated in the Israeli population. We discussed this point in the study limitations. Please see our reply to Prof. Leja, point #1.
Following, the suggestion raised by Prof. Song, we performed a sensitivity analysis. Based on a systematic review that assessed the validity of Biohit ELISA (1), most studies utilized a PGI: PGII ratio <3; and in some, this was in combination with PGI levels that were mostly in the range of 25-50 µg/L. Therefore, in the sensitivity analysis we used the following definitions for atrophic gastritis: PGI<40 µg/L or PGI: PGII<3 PGI<50 µg/L or PGI: PGII<3
The overall prevalences of atrophic gastritis were 7.8% and 9.3%, when applying these definitions, respectively. The respective prevalences among Jewish vs Arab participants were 6.1% vs 9.0% (p=0.028) and 7.2% vs 10.7% (p=0.016).
Multivariable models using the definitions for atrophic gastritis showed similar results to those obtained using the pre-planned case definition of atrophic gastritis, PGI<30 or PGI: PGII<3 (please see the table below).
Please see page 8s last paragraph, page 9 lines 1-2, page 17 paragraph 2 and supplementary table 1.
b) the ELISA method is very sensitive, so I suggest authors provided more information about the lab procedure: e.g. any quality control? all samples were tested in one day? in the same lab?
Reply: All assays were performed in one laboratory at Tel University by an experienced technician. Each ELISA plate included sera from both Arab and Jewish participants, in addition to positive and negative controls and calibrators that were provided in the kits. All quality control measures provided in the kits' inserts were met. Repeated tests of sub-samples PGI (n=26) and PGII (n=16) on two different occasions showed high correlations between the two measurements: Pearson correlation coefficients 0.98 and 0.97, respectively. Following the reviewer's comment, we added this information to the text. Please see page 8 paragraph 1.
'Study design and population' part : please specify how the weight and height were measured? or they are self-reported?
Reply: Height and weight were measured without shoes and with light clothing. Weight in kilograms was measured to the nearest 100 grams using an analog scale, and standing height was measured to the nearest 0.1 centimeter. Following the reviewer's comment, we added this information to the methods section. Please see page 7 paragraph 1.
In the discussion part, the authors summarized evidence of risk factors from previous studies worldwide. I might suggest the authors mention studies from the same region (Israel or neighbor countries), if any, to help us have a better understanding of their results. Also, any comment on the low response rate of Jew participants on the results?
Reply: Limited evidence exists on the prevalence and correlates of atrophic gastritis from the Middle East. In view of the reviewer's comment we cited a previous study from the region, which showed a 4.1% prevalence of atrophic gastritis among persons aged 35-99 years from Iran, when using a cutoff value of PGI: PGII ratio<3 (2). Please see page 18 paragraph 2 and reference # 29 Indeed, the response rate among Jewish participants was relatively low. We added this to the study limitations. Please see page 22 paragraph 1.
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